Endometrial cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. A patient who underwent first uterine surgery at the Fudan University Cancer center and had no surgical contraindications; 2. A patient who signed an informed consent form and was willing to complete the study in accordance with the program; 3. The case group was diagnosed as endometrial cancer by pathology. The control group had no endometrial cancer after pathological diagnosis (endometrial atypical hyperplasia and normal endometrium with benign lesions to remove the uterus); 4. Aged 18-80 years old; 5. Clinical data (clinical diagnosis, pathological tissue staging, postoperative results, etc.) and follow-up data were complete.
Exclusion criteria
Exclusion criteria: 1) Those who have received radiotherapy or chemotherapy before surgery; 2) Those with a history of other malignant tumors, appropriate treatment of basal cells or squamous cell skin cancer, cervical carcinoma in situ or other cancer patients who have survived for more than 5 years can be enrolled; 3) Hyperglycemia patients whose drugs cannot be controlled, routine blood glucose >11.0mmol/L combined with clinical surgical pointers do not meet the surgical conditions; 4) thyroid dysfunction, TT3 (serum total T3) > 4.5nmol/L, TT4 (serum total thyroxine) >230nmol/L, FT4 (serum free thyroxine) >38pmol/L, FT3 (serum free T3) 17pmol/L, uTSH (supersensitive thyrotropin) <0.5 milliunits/liter. 5) Participate in another clinical trial within 30 days prior to randomization and receive study medication and any concomitant treatment with study medication; 6) Those with immunodeficiency or HIV infection; 7) severe heart, lung, liver and kidney dysfunction; 8) Uncontrolled infections or active infections; 9) pregnant, lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| survivorship; | — |
Countries
China
Contacts
Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences